



NICC Program

• The International Nosocomial Infection Control Consortium (INICC) (www.INICC.org) is a non-profit, open, multi-center, international, collaborative program modeled on the US National Nosocomial Infection Surveillance system (NNIS).

•It is the first international research network, formed in 1998, and is responsible for much national and global progress.

•Founded in Argentina, it is a prospective, targeted, outcome and process surveillance system designed to identify and reduce HAI rates and their consequences in the participating facilities.

INICC Program

NICC employs a multiple-approach strategy combining the following interventions:
outcome surveillance;
process surveillance;
performance feedback;
targeted interventions guided by risk factor analysis;
cost- effective interventions guided by cost analysis;
tutorial for surveillance;
training in infection control guidelines application;
secretarial and administrative support in entering data and developing charts;
scientific data analysis and data interpretation to guide actions;
sharing data at scientific meetings and in peer reviewed journals;
and cooperating with hospitals and organizations worldwide.

INICC Program

• Hospitals review the protocol with their research committees and agree to full participation signing a commitment sheet, and sending it to the INICC central office in Buenos Aires, which then provides analysis and reports monthly, answers questions and augments the tutorial with personal instruction when needed.

INICC Program

• Forms and software designed to record patient data are used for both control patients without HAI and for cases with HAI.

•These patients forms include name, medical record, age, gender, underlying diseases, and severity of illness score at the time of entrance to the ICU. On a daily basis, information regarding temperature, blood pressure, devices days, cultures taken, and presence of clinical pneumonia, antibiotic use, and characteristics of any infection are collected both for cases and controls.


•Thus, by outcome surveillance it is also possible to analyze cases and controls in a prospective cohort nested study.

INICC Program


•At the same time, process surveillance and performance feedback is done for hand hygiene compliance, vascular and urinary catheter care, and mechanical ventilator care.


INICC Program


•In 2005 INICC has joined with the International Federation of Infection Control (IFIC) because both organizations concur on the same vision and mission.






















| National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007 | | | | | | | | | |
|---|---|---|---|---|--|--|---|---|--|
| | an R. Edwards, MS. Kel | | | | | | | | |
| | et A. Dudeck, MPH, Rat lanta, Georgia | nay b. Mincey, BA | , Lanier A. Pollock, ML | | | | 007:35:290-301. | | |
| | | تحريبا تسعينات مرباه | on of control line. | annonineed DC | 1 | | I annound line | tiliza | tion |
| | | ule distributi | on or central line. | associated ba | orrau | es and | i central line u | CITER | |
| | | | on or central line | associated ba | orrau | es and | | | |
| atios, by type of location, E | DA module, 2006 | | | | | | Percentile | | |
| ratios, by type of location, [Central line-associated BSI rat | DA module, 2006 | | | | | | Percentile | | |
| atios, by type of location, [Central line-associated BSI rat Type of location | DA module, 2006 | | | | | | Percentile | | |
| ratios, by type of location, [Central line-associated BSI rat Type of location Burn ICU | DA module, 2006 e* No. of locations | No. of CLAB | Central line-days | Pooled mean | | | Percentile | | 90% |
| atios, by type of location, E Central line-associated BSI rat Type of location Burn ICU Coronary ICU Surgical cardiothoracic ICU | A module, 2006 * No. of locations 14 53 51 | No. of CLAB | Central line-days | Pooled mean | 10% | 25% | Percentile 50% (median) 2.0 1.2 | 75% | 90% 6.5 |
| atios, by type of location, E Central line-associated BSI rate Type of location Burn ICU Soronary ICU Burgical cardiothoracic ICU Hedical ICU | No. of locations | No. of CLAB | Central line-days 18,612 63,941 | Pooled mean 6.8 2.8 | 0.0 | 25% | Percentile 50% (median) 2.0 | 75% | 90% 6.5 4.1 |
| atios, by type of location, E Central line-associated BSI rate Type of location Burn ICU Soronary ICU Burgical cardiothoracic ICU Hedical ICU | A module, 2006 * No. of locations 14 53 51 | No. of CLAB 127 181 150 | Central line-days 18,612 63,941 92,484 170,719 | Pooled mean 6.8 2.8 1.6 2.9 | 1 0% | 25% 0.0 0.0 | Percentile 50% (median) 2.0 1.2 2.2 | 75% | 90% 6.5 4.1 |
| ratios, by type of location, D Central line-associated BSI rate Type of location Burn ICU Coronary ICU Surgical cardiothoracic ICU Hedical ICU Hedical ICU Medical ICU Medical ICU | DA module, 2006 e* No. of locations 14 53 51 73 63 | No. of CLAB | Central line-days 18,612 63,941 92,484 170,719 128,502 | Pooled mean 6.8 2.8 1.6 2.9 2.4 | 1 0% | 25% 0.0 0.0 | Percentile 50% (median) 2.0 1.2 | 75% | 90% 6.5 4.1 |
| ratios, by type of location, [Central line-associated BSI rat Type of location Barn ICU Coronary ICU Sorgal ardiothranic ICU Medical ICU Medical/surgal ICU Major teaching All others | DA module, 2006 e* No. of locations 14 53 51 73 63 102 | No. of CLAB 127 181 150 489 304 431 | Central line-days 18,612 63,941 92,484 170,719 128,502 198,551 | Pooled mean 6.8 1.6 2.9 2.4 2.2 | 0.0 0.0 0.0 | 25% 0.0 0.0 0.8 | Percentile 50% (median) 2.0 1.2 2.2 | 75% 4.2 2.8 4.2 | 90% 6.5 4.1 6.2 5.5 |
| ratios, by type of location, [Central line-associated BSI rate Type of location Jarms (CU Sormary (CU wrgsal cardiothoracia (CU +edical (CU +edical ICU +edical ICU +edical ICU Major teaching All others relation: medial/surgeal (CU | DA module, 2006 e* No. of locations 14 53 51 73 63 102 36 | No. of CLAB | Central line-days 18,612 63,941 92,484 170,719 128,502 198,551 48,144 | Pooled mean 6.8 2.8 1.6 2.9 2.4 2.2 5.3 | 0.0 0.0 0.0 0.0 | 25% 0.0 0.8 0.6 | Percentile 50% (median) 2.0 1.2 2.2 1.9 | 4.2 2.8 4.2 3.1 | 90% 6.5 4.1 6.2 5.5 4.5 |
| ratios, by type of location, [Central line-associated BSI rat Type of location Jam RCU Coronary RCU Wingsal ardothoracic ICU Medical ICU Medical ICU Medical ICU Major teaching All others All others Neurosurgical ICU | DA module, 2006 * No. of locations 14 53 51 73 63 102 36 19 | No. of CLAB | Central line-days 18,612 63,941 92,484 170,719 128,502 198,551 | Pooled mean 6.8 2.8 1.6 2.9 2.4 2.2 5.3 3.5 | 0.0 0.0 0.0 0.0 0.0 | 0.0 0.0 0.8 0.6 0.0 | Percentile 50% (median) 2.0 1.2 2.2 1.9 1.0 3.5 | 4.2 2.8 4.2 3.1 2.3 | 90% 6.5 4.1 6.2 5.5 4.5 |
| ratios, by type of location, D Central line-associated BSI rat Fype of location Jam (CU Sorony) (CU Wingsi and/otherace (CU Wingsi and/otherace (CU Wedsal/Wagal (CU Neurosingsal (CU Neurosingsal (CU | DA module, 2006 e* No. of locations 14 53 51 73 63 102 36 19 72 | No. of CLAB | Central line-days 18,612 63,941 92,484 170,719 128,502 198,551 48,144 | Pooled mean 6.8 2.8 1.6 2.9 2.4 2.2 5.3 | 0.0 0.0 0.0 0.0 0.0 | 0.0 0.0 0.8 0.6 0.0 | Percentile 50% (median) 2.0 1.2 2.2 1.9 1.0 3.5 2.0 | 4.2 2.8 4.2 3.1 2.3 | 90% 6.5 4.1 6.2 5.5 4.5 |
| ratios, by type of location, I Central line-associated BSI rat Type of location Burn ICU Coronary ICU Surgial cardiothoracic ICU Medical ICU Medical ICU Medical ICU Major teaching All others Pedarics medical/surgical ICU Neurosurgical ICU Surgial ICU | DA module, 2006 * No. of locations 14 53 51 73 63 102 36 19 | No. of CLAB | Central line-days 18,612 63,941 92,484 170,719 188,502 198,551 48,144 21,412 | Pooled mean 6.8 2.8 1.6 2.9 2.4 2.2 5.3 3.5 | 0.0 0.0 0.0 0.0 0.0 0.0 0.0 | 0.0 0.0 0.8 0.6 0.0 1.1 | Percentile 50% (median) 2.0 1.2 2.2 1.9 1.0 3.5 | 4.2 2.8 4.2 3.1 2.3 6.5 | 90% 6.5 4.1 6.2 5.5 4.5 9.4 |
| | DA module, 2006 e* No. of locations 14 53 51 73 63 102 36 19 72 | No. of CLAB | Central line-days 18,612 63,941 92,484 170,719 128,502 198,551 48,144 21,412 137,484 | 6.8 2.8 1.6 2.9 2.4 2.2 5.3 3.5 2.7 | 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 | 25% 0.0 0.0 0.8 0.6 0.0 1.1 0.9 | Percentile 50% (median) 2.0 1.2 2.2 1.9 1.0 3.5 2.0 | 4.2 2.8 4.2 3.1 2.3 6.5 4.4 | 90% 6.5 4.1 6.2 5.5 4.5 9.4 7.4 |

| Urinary catheter-associated | | | Urinary | | _ | | Pe | rcentile | | | |
|---|---|---|--|---|---------------|--|---------------------------------|--|---------------------|--|-------------------------|
| UTI rate* | No. of locations | No. of CAU | catheter-days | Pooled mean | 10% | 25% | 50% | (median) | 75% | 90 | 6 |
| Type of location | | | | | | | | | | | ~ |
| Burn ICU | 12 | 96 | 12.860 | 7.5 | | | | | | | |
| Coronary ICU | 41 | 301 | 65,277 | 4.6 | 0.9 | 2.8 | | 4.0 | 5.5 | 81 | |
| Surgical cardiothoracic ICU | 41 | 262 | 70,221 | 3.7 | 0.0 | 1.8 | | 3.4 | 4.3 | 7.5 | |
| Medical ICU | 55 | 680 | 156.261 | 4.4 | 0.7 | 1.8 | | 3.8 | 5.6 | 8.3 | |
| Medical/surgical ICU | | | | | | | | 5.0 | 5.6 | 0.2 | |
| Major teaching | 51 | 450 | 132.096 | 3.4 | 0.4 | 19 | | 3.0 | 4.5 | 6.4 | |
| All others | 83 | 697 | 221.435 | 3.1 | 0.0 | 0.8 | | 2.4 | 4.2 | 6.5 | |
| Pediatric medical/surgical ICU | 27 | 113 | 21.686 | 5.2 | 0.0 | 0.0 | | 2.8 | 6.0 | 9.1 | |
| Neurosurgical ICU | 14 | 171 | 26.253 | 6.5 | 4.4 | | | | 0.0 | 7.3 | |
| Surgical ICU | 54 | 509 | 126.887 | 40 | 0.0 | 1.2 | | 3.0 | 61 | 99 | |
| Trauma ICU | 19 | 283 | 51.027 | 5.5 | 0.0 | 1.4 | | 3.0 | 0.1 | 7.7 | |
| inpatient medical ward | 11 | 110 | 15.448 | 71 | | | | | | | |
| inpatient medical/surgical ward | 25 | 87 | | | | | | | | | |
| Table 4. Pooled means a | ind key percentil | es of the distr | 23,416 ibution of vent | 3.7 ilator-associal | 0.0 ced PN | 1.5 NEU r | ates a | 2.9 nd ventila | 5.0 tor u | 7.7 tiliza | |
| | ind key percentil | es of the distr | | | | | ates a | | tor u | | |
| Table 4. Pooled means a | ind key percentil n, DA module, 2 | es of the distr 006 | | ilator-associal | ted PN | IEU r | | nd ventila | tor u | tiliza | tion |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU | ind key percentil n, DA module, 2 | es of the distr 006 | ibution of vent | ilator-associal | ted PN | IEU r | | nd ventila Percenti | tor u | tiliza | tion |
| Table 4. Pooled means a ratios, by type of location | ind key percentil n, DA module, 2 | es of the distr 006 | ibution of vent | ilator-associal | ted PN | IEU r | | nd ventila Percenti | tor u | tiliza | tion |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Type of location Burn ICU | ind key percentil n, DA module, 2 I rate* No. of un | es of the distr 006 its No. of VA | P Ventilator d | ilator-associal ays Pooled m | ean | 10% | 25% | nd ventila Percenti 50% (medi | tor u | tiliza | 90 |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Type of location Burn ICU Correary ICU | ind key percentil n, DA module, 2 I rate* No. of un 12 48 | es of the distr 006 its No. of VA 124 100 | P Ventilator d | ilator-associat ays Pooled m 12.3 2.8 | ean | NEU r | 25% | nd ventila Percenti 50% (medi | tor ut le an) | tiliza 75% 4.5 | tion 90 |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Type of location Bum ICU Coronary ICU Surgicil cardochracic ICU | ind key percentil n, DA module, 2 I rate* No. of un | es of the distr 006 its No. of VA 124 100 265 | ibution of vent P Ventilator d 10,098 35,727 46,710 | ilator-associal ays Pooled m | ean | 10% | 25% | nd ventila Percenti 50% (medi 1.3 4.0 | tor ut le an) | tiliza | 90 6 19 |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Type of location Burn ICU Correstry ICU Surgest eardiothoracie ICU Medical ICU | Ind key percentil n, DA module, 2 I rate* No. of un 12 48 48 | es of the distr 006 its No. of VA 124 100 | P Ventilator d | ays Pooled m 12.3 2.8 5.7 | ean | NEU r | 25% 0.0 1.4 | nd ventila Percenti 50% (medi | tor ut le an) | tiliza 75% 4.5 8.1 | 90 6 19 |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Type of location Burn ICU Goreary ICU Medical ICU Medical ICU Medical ICU | nd key percentil n, DA module, 2 I rate* No. of un 12 48 48 64 | es of the distr 006 its No. of VA 124 100 265 339 | P Ventilator d 10,098 35,727 46,710 109,277 | ays Pooled m 12.3 2.8 5.7 3.1 | ean | 0.0 0.0 0.0 | 25% 0.0 1.4 0.9 | nd ventila Percenti 50% (medi 1.3 4.0 2.8 | tor ut le an) | 4.5 8.1 4.6 | 90 6 19 7 |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Type of location Barn ICU Corrostry ICU Surgical cardiothoracis ICU Medical ICU Medical ICU Major tesching | Ind key percentil n, DA module, 2 I rate* No. of un 12 48 48 64 58 | es of the distr 006 its No. of VA 124 100 265 339 302 | P Ventilator d 10,098 35,727 46,710 109,277 84,530 | ilator-associat ays Pooled m 12.3 2.8 5.7 3.1 3.6 | ean | 0.0 0.0 0.0 0.0 | 0.0 1.4 0.9 1.3 | nd ventila Percenti 50% (medi 1.3 4.0 2.8 2.5 | tor ut le an) | tiliza 75% 4.5 8.1 4.6 5.1 | 90 6 19 7 7 |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Type of location Burn ICU Coreary ICU Surgeal cardiochancie ICU Media/Lurgeal ICU Mijor teaching All others | ind key percentil n, DA module, 2 I rate* No. of un 12 48 48 64 58 99 | es of the distr 006 its No. of VA 124 100 265 339 302 372 | P Ventilator d 10.098 35.727 46.710 109.277 84.530 135.546 | ays Pooled m 12.3 2.8 5.7 3.1 3.6 2.7 | ean | 0.0 0.0 0.0 0.0 0.0 0.0 | 0.0 1.4 0.9 1.3 0.0 | nd ventila Percenti 50% (medi 1.3 4.0 2.8 2.5 1.6 | tor ut le an) | tiliza 75% 4.5 8.1 4.6 5.1 3.8 | 90 6 19 7 6 |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Som RCU Consolitation account Medical RCU Medical RCU RCU RCU RCU RCU RCU RCU RCU RCU RCU | ind key percentil n, DA module, 2 I rate* No. of un 12 48 48 48 64 58 99 32 | es of the distr 006 its No. of VA 124 100 265 339 302 372 81 | P Ventilator d 10,098 35,727 46,710 109,277 84,530 135,546 32,936 | ays Pooled m 12.3 2.8 5.7 3.1 3.6 2.7 2.5 | ean | 0.0 0.0 0.0 0.0 | 0.0 1.4 0.9 1.3 | nd ventila Percenti 50% (medi 1.3 4.0 2.8 2.5 | tor ut le an) | tiliza 75% 4.5 8.1 4.6 5.1 | 90 6 19 7 6 |
| Table 4. Pooled means a ratios, by type of location Ventilator-associated PNEU Type of location Burn ICU Coreary ICU Surgeal cardiochancie ICU Media/Lurgeal ICU Mijor teaching All others | ind key percentil n, DA module, 2 I rate* No. of un 12 48 48 64 58 99 | es of the distr 006 its No. of VA 124 100 265 339 302 372 | P Ventilator d 10.098 35.727 46.710 109.277 84.530 135.546 | ays Pooled m 12.3 2.8 5.7 3.1 3.6 2.7 | ean | 0.0 0.0 0.0 0.0 0.0 0.0 | 0.0 1.4 0.9 1.3 0.0 | nd ventila Percenti 50% (medi 1.3 4.0 2.8 2.5 1.6 | tor ut le an) | tiliza 75% 4.5 8.1 4.6 5.1 3.8 | tion |

Surveillance Outcome surveillance

• Outcome surveillance is the measurement of the rates and consequences of health care-associated infections (HAI), including but not limited to the following few variables: HAI rates, mortality, extra length of stay, attributable cost, and bacterial resistance.

•Development of infection control programs in industrialized countries has been supported by outcome surveillance data. Baseline epidemiology should include the above-mentioned items in order to plan specific targeted interventions, the most relevant one being the HAI rate.

Surveillance Outcome surveillance

• Outcome surveillance allows evaluation of the costeffectiveness of specific infection control interventions.

• It is also used to analyze case control studies in order to establish risk factors, and match patients to find extra cost and mortality. In summary, outcome surveillance is often the infrastructure for management of HAI.

Surveillance Outcome surveillance

 Outcome surveillance of device-associated infections (DAI) has become an integral feature of infection control and quality assurance in the industrialized countries since more precise assignment of risk is possible.

•Standards for institutional surveillance have been adopted in the United States, UK, Australia, Canada, Germany, among other countries.

Surveillance Outcome surveillance

 These industrialized countries report infection rates as DAI per 1000 device days, allowing them to further analyze the impact of specific risk factors and guide their targeted interventions.

•Developing countries more frequently report percentage (cases over discharges or admissions) of HAI.

Surveillance Outcome surveillance

• Risk for infection is higher among seriously ill patients who often have several indwelling devices; thus, the higher infection rates in ICUs.

 Since the denominator of number of device days is unknown, it is impossible to compare rates among the hospitals and the rates are less useful for comparisons of time periods within the same hospital because the specific risk factor is not captured.


Surveillance Outcome surveillance

•Sometimes HAI rate is reported as number of infections per 1000 patient days, but again the rates may not be compared because of the lack of appropriate denominators.


Device days were reported in few recent studies and infection rates were calculated by number of infections per 1000 device days following NHSN (formerly NNIS) methodology.


INICC Program


• INICC has reported HAI and mortality rates from several participating hospitals that applied both outcome and process surveillance.












| | | | ection Control in | | | | | |
|---|--|---|---|--|--|--|--|--|
| | | Dev | zeloping Countries | | | | | |
| | Patricia Lynch, Victor D. Rosenthal, Michael A. Borg, and Serger R. | | | | | | | |
| TABLE 18 | | | | | | | | |
| | Y THE WORLD BANK | | Y HOSPITALS FROM COUNTRIES | | | | | |
| | | | | | | | | |
| Country | Type of Study/Unit | Type of HAI | HAI Rate | Year | Reference | | | |
| | Type of Study/Unit Multicenter adult ICU | Type of HAI | 30.3 per 1,000 central line days | Year 2004 | Reference [71] | | | |
| Argentina | 31 3 | IVD-BSI* IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days | | | | | |
| Argentina Brazil | Multicenter adult ICU | IVD-BSI* | 30.3 per 1,000 central line days | 2004 | [71] | | | |
| Argentina Brazil Brazil | Multicenter adult ICU Multicenter adult ICU | IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 17.3 to 34.9 per 1,000 central line days 11.3 per 1,000 central line days | 2004 2006 2004 2006 | [71] [45] | | | |
| irgentina irazil colombia | Multicenter adult ICU Multicenter adult ICU Multicenter new born ICU Multicenter adult ICU Adult ICU | IVD-BSI* IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 17.3 to 34.9 per 1,000 central line days 11.3 per 1,000 central line days 8.3 per 1,000 central line days | 2004 2006 2004 2006 2006 | [71] [45] [44] [50] [51] | | | |
| irgentina irazil Colombia Croatia gypt | Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU Multicenter new born ICU Multicenter adult ICU Adult ICU Pediatric ICU | IVD-BSI* IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 17.3 to 34.9 per 1,000 central line days 11.3 per 1,000 central line days 8.3 per 1,000 central line days 18.7 per 1,000 central line days | 2004 2006 2004 2006 2006 2006 | [71] [45] [44] [50] | | | |
| Argentina Brazil Srazil Colombia Croatia Gypt ndia | Multicenter adult ICU Multicenter adult ICU Multicenter new born ICU Multicenter adult ICU Adult ICU Pediatric ICU Multicenter adult ICU | IVD-BSI* IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 17.3 to 34.9 per 1,000 central line days 11.3 per 1,000 central line days 8.3 per 1,000 central line days 18.7 per 1,000 central line days 11.1 per 1,000 central line days | 2004 2006 2004 2006 2006 2005 2005 | [71] [45] [44] [50] [51] [52] [53] | | | |
| Argentina Brazil Colombia Croatia Gypt ndia Mexico | Multicenter adult ICU Multicenter adult ICU Multicenter new born ICU Multicenter adult ICU Adult ICU Pediatric ICU Multicenter adult ICU Multicenter adult ICU | IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 17.3 to 34.9 per 1,000 central line days 8.3 per 1,000 central line days 18.7 per 1,000 central line days 11.1 per 1,000 central line days 23.1 per 1,000 central line days | 2004 2006 2004 2006 2006 2005 2005 2005 | [71] [45] [44] [50] [51] [52] [53] [56] | | | |
| Argentina Brazil Colombia Croatia Egypt ndia Mexico Mexico | Multicenter adult ICU Multicenter adult ICU Multicenter new born ICU Multicenter adult ICU Adult ICU Pediatric ICU Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU | IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 17.3 to 34.9 per 1,000 central line days 11.3 per 1,000 central line days 18.3 per 1,000 central line days 18.7 per 1,000 central line days 19.1 per 1,000 central line days 23.1 per 1,000 central line days 24.6 per 1,000 central line days | 2004 2006 2004 2006 2006 2005 2005 2005 2006 2001 | [71] [45] [44] [50] [51] [52] [53] [56] [72] | | | |
| rrgentina irazil colombia croatia gypt rdia Aexico Aexico Aorocco | Multicenter adult ICU Multicenter adult ICU Multicenter new born ICU Adult ICU Pediatric ICU Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU Pediatric ward Adult medical ICU | IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 11.3 to 34.9 per 1,000 central line days 11.3 per 1,000 central line days 10.3 per 1,000 central line days 11.1 per 1,000 central line days 23.1 per 1,000 central line days 24.0 per 1,000 central line days 25.0 per 1,000 central line days | 2004 2006 2004 2006 2006 2005 2005 2005 2006 2001 2005 | [71] [45] [50] [51] [52] [53] [56] [72] [57] | | | |
| rgentina irazil irazil iroatia gypt idia Aexico Aexico Aexico eru | Multicenter adult ICU Multicenter adult ICU Multicenter new born ICU Multicenter adult ICU Adult ICU Pediatric ICU Multicenter adult ICU Multicenter adult ICU Pediatric vard Adult medical ICU Multicenter adult ICU | IVD-BSI* IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 11.3 per 1,000 central line days 11.3 per 1,000 central line days 18.7 per 1,000 central line days 18.7 per 1,000 central line days 23.1 per 1,000 central line days 23.6 per 1,000 central line days 5.8 per 1,000 central line days 5.8 per 1,000 central line days | 2004 2006 2004 2006 2005 2005 2005 2006 2001 2005 2005 | [71] [45] [50] [51] [52] [53] [56] [57] [57] [58] | | | |
| rgentina irazil colombia croatia gypt rdia Aexico Aexico Aorocco eru hilippines | Multicenter adult ICU Multicenter adult ICU Multicenter new bom ICU Multicenter new bom ICU Adult ICU Padiatric ICU Multicenter adult ICU Padiatric Vard Adult medical ICU Multicenter adult ICU Adult medical ICU Multicenter adult ICU Adult Multicenter adult ICU | IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 IVD-851 | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 11.3 per 1,000 central line days 11.3 per 1,000 central line days 18.7 per 1,000 central line days 18.7 per 1,000 central line days 26.0 per 1,000 central line days 26.0 per 1,000 central line days 26.0 per 1,000 central line days 8.8 per 1,000 central line days 8.8 per 1,000 central line days | 2004 2006 2004 2006 2005 2005 2005 2006 2001 2005 2005 2005 2005 | [71] [45] [44] [50] [51] [53] [56] [57] [58] [59] | | | |
| rgentina irazil colombia croatia gypt ndia dexico Aexico Aexico Aerocco ieru hilippines urkey | Multicenter adult ICU Multicenter adult ICU Multicenter new bom ICU Multicenter new bom ICU Adult ICU Pediatric Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU Adult ICU Hospitalwide | IVD-BSI* IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 17.3 to 34 per 1,000 central line days 8.3 per 1,000 central line days 11.1 per 1,000 central line days 23.1 per 1,000 central line days 24.6 per 1,000 central line days 25.6 per 1,000 central line days 26.6 per 1,000 central line days | 2004 2006 2004 2006 2005 2005 2005 2005 2005 2005 2005 | [71] [45] [44] [50] [51] [52] [53] [56] [57] [57] [58] [59] [73] | | | |
| Argentina Brazil Brazil Colombia Croatia Egypt India Mexico Mexico Mexico Mexico Peru Philippines Turkey Turkey Turkey | Multicenter adult ICU Multicenter adult ICU Multicenter new born ICU Multicenter new born ICU Adult ICU Pediatric ICU Multicenter adult ICU Adult medicalt ICU Adult medical ICU Multicenter adult ICU Hospitalwide Multicenter adult ICU | IVD-BSI* IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 11.3 per 1,000 central line days 11.3 per 1,000 central line days 18.7 per 1,000 central line days 18.7 per 1,000 central line days 26.0 per 1,000 central line days 26.0 per 1,000 central line days 26.6 per 1,000 central line days 27.8 per 1,000 central line days 28.6 per 1,000 central line days 29.2 per 1,000 central line days | 2004 2004 2004 2006 2006 2005 2005 2006 2001 2005 2005 2005 2005 2004 2004 | [71] [45] [44] [50] [51] [52] [53] [54] [57] [57] [58] [59] [73] [66] | | | |
| Country Argentina Brazil Brazil Colombia Croatia Egypt India Mexico Mexico Mexico Mexico Mexico Meruco Peru Philippines Turkey Turkey Saudi Arabia INICC | Multicenter adult ICU Multicenter adult ICU Multicenter new bom ICU Multicenter new bom ICU Adult ICU Pediatric Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU Multicenter adult ICU Adult ICU Hospitalwide | IVD-BSI* IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI IVD-BSI | 30.3 per 1,000 central line days 9.2 per 1,000 central line days 17.3 to 34 per 1,000 central line days 8.3 per 1,000 central line days 11.1 per 1,000 central line days 23.1 per 1,000 central line days 24.6 per 1,000 central line days 25.6 per 1,000 central line days 26.6 per 1,000 central line days | 2004 2006 2004 2006 2005 2005 2005 2005 2005 2005 2005 | [71] [45] [44] [50] [51] [52] [53] [54] [52] [53] [54] [57] [58] [59] [73] | | | |

| Consortium Intensive Care Uni | ts* | | | | | | | | |
|--|-------------------|-------------------|--------------------|------------------|--------------------|-------|------------------|--------------------|---------------|
| Variable | | | | Count | try | | | | Overall |
| | A | В | с | D | E | F | G | н | |
| CVC-associated bloodstream infections. n | 119 | 86 | 126 | 109 | 151 | 11 | 35 | 293 | 930 |
| Rate per 100 patients (range)† | 1.3 (0.0-13.0) | 8.4 (0.0-11.3) | 5.8 (0.0-9.0) | 3.2 (0.0-5.2) | 10.0 (1.0-15.2) | 2.7# | 2.6 (0.0-3.3) | 12.7 (1.0-47.6) | 4.4 (1.3-12.7 |
| Rate per 1000 CVC days (range)† | 10.7 (0.0-18.9) | 9.2 (0.0-25.8) | 11.3 (0.0-20.3) | 8.8 (0.0-15.4) | 16.3 (4.2-23.3) | 18.5‡ | 7.8 (0.0-10.7) | 17.9 (6.0-41.5) | 12.5 |
| Proportion of cases, %§ | | | | | | | | | |
| Enterobacteriaceae | 31 | 26 | 31 | 42 | 29 | 33 | 19 | 22 | 27 |
| Pseudomonas aeruginosa | 10 | 5 | 5 | 13 | 15 | 18 | 10 | 9 | 9 |
| Acinetobacter spp. | 4 | 8 | 7 | 10 | 5 | 9 | 5 | 22 | 13 |
| Staphylococcus aureus | 34 | 20 | 37 | 8 | 8 | 18 | 38 | 26 | 25 |
| Enterococci | 1 | 5 | 1 | 5 | 0 | 0 | 0 | 4 | 3 |
| Coagulase-negative staphylococci | 20 | 30 | 14 | 8 | 38 | 9 | 5 | 13 | 18 |
| Candida spp. | 1 | 7 | 2 | 10 | 6 | 9 | 24 | 4 | 5 |
| Susceptibility of resistant microorganisms, % | | | | | | | | | |
| MRSA | 64 | 100 | 70.6 | 100 | 0 | 31 | 80 | 92 | 85 |
| Ceftriaxone-resistant Enterobacteriaceae | 31 | 100 | 33.3 | 71 | 50 | 95 | 50 | 100 | 57 |
| Fluoroquinolone-resistant P. aeruginosa | 56 | 70 | 0.0 | 0 | 100 | 0 | 100 | 51 | 49 |
| Vancomycin-resistant enterococci | 9 | 0 | 0.0 | 0 | 0 | 0 | 0 | 0 | 3 |



Surveillance Outcome Surveillance

Rates of DAI in developing countries were far higher than reported by the NHSN system:

 the overall rate of CVC associated BSI in the International Nosocomial Infection Control Consortium (INICC) medical–surgical ICUs, 11.4 per 1000 CVC days, is around six-fold higher than the 2 per 1000 CVC-days reported for comparable U.S. ICUs by NHSN;

• the overall rate of CAUTI was also higher, 7.4 as compared with 2 per 1000 catheter-days.

 and the overall rate of VAP was also higher than pooled NNIS rates, 21.4 vs. 4 per 1000 ventilator-days;

Surveillance Outcome Surveillance

There are a number of explanations for the higher rates of DAI representative of developing country

ICUs, as previously suggested by several investigators:

 Most developing countries do not have mandatory laws for HAI control programs, and also hospital accreditation is not mandatory. Hand hygiene is highly variable.

•There are very limited funds and resources for infection control, and nurse-to-patient staffing ratios are lower than in most industrialized countries ICUs.

 Use of outdated technology is also a factor: i.e., developing countries use open intravenous infusion and urinary collection systems rather than closed systems that are the standard of care in industrialized countries.


Surveillance Outcome Surveillance


 In developing countries even with different health care systems, generally, the perception is that rates of HAI are low and that compliance with hand hygiene recommendations always occurs. However, frequently, no formal outcome and process surveillance is conducted to validate the perception.


•Outcome surveillance of DAIs defines the magnitude of the problem, identifies the highest risk devices, and provides the framework for planning to reduce infection risk.


Surveillance Outcome Surveillance

• Outcome surveillance also allow measuring other variables as length of stay, mortality and cost









| Table 1. Baseline characte | ristics of patier | nts |
|---|----------------------------|------------------------------|
| | Case patients (N = 142) | Control patient (N = 142) |
| Average length of stay \geq 7d (%) | 142 (100) | 142 (100) |
| Mean age (SD) | 70.09 (±14.17) | 68.88 (±13.74)* |
| No. males (%) | 83 (58.5) | 83 (58.5)* |
| No. admitted to medical/surgical ICU (%) | 116 (81.7) | 116 (81.7)* |
| Mean ASIS (SD) | 3.30 (±1.08) | 3.09 (±0.90)* |
| Number included in study by year (%) | | |
| 1998 | 25 (17.6) | 27 (19.0) |
| 1999 | 50 (35.2) | 49 (34.5) |
| 2000 | 46 (32.4) | 37 (26.1) |
| 2001 | 19 (13.4) | 27 (19.0) |
| 2002 | 2 (1.4) | 2 (1.4) |

Rosenthal VD, et al. Am J Infect Control 2003;31(8):475-80.

The attributable cost, length of hospital stay, and mortality of central line-associated <u>BLOODSTREAM INFECTION</u> in intensive care departments in Argentina: A prospective, matched analysis. Case (N= 142) Control (N= 142) Extra Expenditures Total days 3,322 1,632 1690 Average length of stay in ICU 23.39 (SE 1.49) 11.49 (SE 0.68) 11.90 Total fixed cost \$830,500 \$408,000 \$422,500 \$5,848 (SE 372.89) \$2,873 (SE 171.07) Mean fixed cost \$2,975 Antibiotic utilization Total antibiotics (in DDD*) 4,568 1,356 3,212 Mean antibiotic use per patient (32.16 (SE 2.81) 9.54 (SE 1.05) 22.62 DDD*) \$271.656 Total cost of antibiotics \$301,488 \$29.832 Mean costs of antibiotics per patient \$2,123 (SE 186.06) \$210 (SE 23.09) \$1,913 \$1,131,988 \$437,832 \$694,156 Aggregate costs \$7,971.74 \$3,083.32 \$4,888.42 Mean aggregate costs per patient Average mortality 77/142 (54.2%) 42/142 (29.6%) 24.6% 44 Rosenthal VD, et al. Am J Infect Control 2003;31(8):475-80.

| The Attributable Cost, And Length Of Hospital Stay Of Central Line Associated <u>BLOOD STREAM INFECTION</u> In Intensive Care Units In Mexico. A Prospective, Matched Analysis. | | | | | | |
|---|---|-----------------|--|---|--|--|
| | Control (N= 55) | Case (N= 55) | Overall Attributable Extra Expenditures | Attributable Extra Expenditure per patient | | |
| Average length of stay in ICU (days) | 406 | 739 | 333 | 6.05 | | |
| Antibiotics (US\$) | 13,354.35 | 46,265.96 | 32,911.61 | 598.39 | | |
| Other medicaments (US\$) | 128,415.14 | 129,832.44 | 1,417.30 | 25.77 | | |
| Disposables (US\$) | 219,345.82 | 308,808.79 | 89,462.97 | 1,626.60 | | |
| Cultures (US\$) | 1,171.40 | 2,111.85 | 940.45 | 17.10 | | |
| Other lab tests (US\$) | 37,441.19 | 61,174.01 | 23,732.82 | 431.51 | | |
| X ray, Scan, etc (US\$) | 15,198.40 | 19,556.44 | 4,358.04 | 79.24 | | |
| Other costs (US\$) | 44,395.46 | 71,105.56 | 26,710.09 | 485.64 | | |
| Hospitalization (fixed costs) (US\$) | 496,326.78 | 954,294.33 | 457,967.55 | 8326.68 | | |
| Total cost (US\$) | 955,648.55 | 1,593,149.38 | 637,500.83 | 11,590.92 | | |
| | Rangel-Frausto M, rol and Hospital Epi | | | 45 | | |

| The Attributable Cost, And Length Of Hospital Stay Of Central Line Associated BLOOD STREAM INFECTION In Intensive Care Units In | |
|--|--|
| Brazil. A Prospective, Matched Analysis | |

•

| | BSI | Controls | Extra | RR | 95 % CI | P- value |
|-------------------------------------|-------------------------|-----------------------|---------|----------|----------------|-------------|
| Total patients (n) | 70 | 140 | | | | |
| Total Antibiotic DDD, (DDD) | 4243 | 2124 | | | | |
| Antibiotic DDD per patient, | 60.61 | 15.17 | 45.44 | | | |
| Total Antibiotic cost (US\$) | 312,225.54 | 99,930.12 | | | | |
| Antibiotic cost per patient, (US\$) | 4,460.36 | 713.78 | 3,746.5 | | | |
| Length of Stay (days) | 30.58 <u>+</u> 20.41 | 6.95 <u>+</u> 4.89 | 23.6 | 4.4 0 | 4.08 – 4.75 | 0.0000 |
| Cost (US\$) | 9,843.35 | 1,937.18 | 7,906 | | | |
| Total deaths (n) | 23 | 45 | | | | |
| Crude mortality (%) | 32.9% | 32.1% | | 1.0 2 | 0.62 - | 0.9316 |

Reinaldo Salomao, Victor D. Rosenthal, et al. APIC Meeting. Tampa, USA. June 2006. 46

| Table 1. Baseline cha | | patients with | and |
|---|-----------------------|-------------------------|---------|
| without nosocomial p | oneumonia | | |
| | Cases, N = 307 (%) | Control, N = 307 (%) | P value |
| LOS (7 or more days) | 307 (100) | 307 (100) | NS |
| Age, mean, SD, years | 73.79 SD 11.97 | 69.90 SD 11.48 | NS |
| Sex (male) | 157/307 (51.1) | 157/307 (51.1) | NS |
| ICU (Ms ICU) | 247/307 (80.5) | 247/307 (80.5) | NS |
| Average severity of illness score, mean, SD | 3.34 SD 0.95 | 3.11 SD 0.83 | NS |
| Year | 1998 (5.2) | 1998 (6.8) | NS |
| | 1999 (20.5) | 1999 (18.9) | |
| | 2000 (24.4) | 2000 (22.8) | |
| | 2001 (43.0) | 2001 (44.6) | |
| | 2001 (6.8) | 2001 (6.8) | |

| The attribu | table cost and | length of hospital | stay because of |
|-------------------|------------------|----------------------------|--|
| nosocomial | NEUMONIA in | intensive care un | its in 3 hospitals in |
| Ar | gentina: a pros | pective, matched | analysis. |
| | Case (N= 307) | Control (N= 307) | Attributable Extra Expenditures |
| Total Days | 6,043 | 3,295 | Total Extra Days: 2,748 |
| Alos | 19.68 | 10.73 | Mean Extra Daya: 8.95 |
| Total Fixed Cost | \$1,510,750 | \$823,750 | Fixed Extra Cost: \$687,000 |
| Mean Fixed Cost | \$4,921 | \$2,683 | M can Extra Cost: \$2,238 |
| Total Atb DDD | 7,815 | 3,181 | Atb Extre DDD: 4,634 |
| Mean Atb DDD | 25.45 | 10.36 | Mean Extra Atb DDD: 15.09 |
| Total Atb Cost | \$515,790 | \$209,946 | Atb Extra Cost: \$305,844 |
| Mean Atb Cost | \$1,680.09 | \$683.86 | Mean Extra Atb Cost: \$996.22 |
| Total Global Cost | \$1,518,565 | \$826,931 | Total Extra Global Cost: \$691,634 |
| Mean Global Cost | \$4,946.46 | \$2,693.58 | Mean Total Extra Global Cost: \$2,252.88 |
| Total Mortality | 195 | 102 | Total Extra Dead: 90 |
| Average Mortality | 63.5% | 33.2% | Extra Attributable Mortality: 30.3% |
| | Rosenthal VD, et | al. Am J Infect Control 20 | 48 105;33(3):157-61. |

Surveillance Process Surveillance

Process surveillance is the standardized collection of data regarding the infection control practices actually used in the facility.

•This includes compliance with recommendations for hand hygiene, vascular catheter care, urinary catheter care, measures to prevent VAP such as position of the head, type of secretion suctioning; and measures to prevent surgical site infections as pre-surgical shower, clipping and antibiotic prophylaxis, or others.

Surveillance Process Surveillance

 Process surveillance is usually done by observation of actual practices, analysis of the data and performance feedback to the personnel who performed the care or are responsible for it.

•Hand hygiene is a fundamental aspect of infection control; several studies reported a decline in HAI rates when compliance with hand hygiene was enhanced.

Surveillance Process Surveillance


 Despite universal acknowledgement of the pivotal role that hand hygiene and device care play in reducing infection risk , hand hygiene compliance among healthcare workers in developing countries remains poor, with rates ranging from 9% to 75%.


 Several interventions have been attempted to improve hand hygiene practices; among the most effective ones are those that emphasize targeted education, process surveillance and frequent performance feedback.

Surveillance Process Surveillance

 Dubbert, et al found that while education alone improved compliance rates in a transient way, process surveillance and performance feedback resulted in sustained improvement in compliance.

 In developing countries, implementation of education, process surveillance and performance feedback, improved considerably the adherence to hand hygiene; examples from developing countries were reported from Argentina, China, Mexico, Russia, Turkey, and others.







Surveillance Process Surveillance

• In Argentina between April 1999 and October 2003; 15,531 patient contacts were observed in one hospital. The baseline rate of HW before contact with patients was 17%. With education and process surveillance and performance feedback, hand hygiene before contact with the patients increased to 58%.

| Improvement of Hygiene Compli | |
|----------------------------------|---|
| | Effect of education and |
| | performance feedback on |
| | handwashing:The benefit of |
| | administrative support in |
| | Argentinean hospitals |
| | View Taniel Rometal Alle MCC** Mark in Sciences Alle Alle S Sanda Corran, R. R. 20 Heat Workshow Alle S Heat Workshow Alle Markon, Waternin Technik Mark, Agentina, and Madoro, Waternin Technik Mark, Alle Markon, Markon Alle Statistica, Mary pre-review Andre Ause 40. |
| | beginstating (UW) significantly reduces happing information and invasion begins for the different of UW by health care works (UW) before constraint with pattern is A Appendium hospitals. We preferred an observational analy of UW to measure the effect of Interventions constraints outcoming the preferred measure feedback. |
| | Methods: A true of 3 hospitalismer matched for additenses to a WB present. The observed WB windowid physicians, running pressource, and anchiny and MB-mini and interventions to additable handres more fifth (quickes 1), as estimated the reflector of education also replaces 2), followed by robustion plan preferencesce feedback-phase 2). We also evaluated the relationship between the administration approximated MP additional administration and administration approximate and MP administration approximate administration approximated MP additional Administration approximated MP additional Administration approximate Administration approximat |
| | Bendri '90 ohnred 15:201 priorie consers in 3 Doppila. The handline and eIW lefter consers with partners was 17%. With doublines, With else consers with the partners account of 4% priorities mits 24% confidence testered 325:50.2 P < 0.01). Mag education and proferances for the MI for their sciences of 10% priorities in strend 125:50.2 P 10:2021 (2010). The grant was an equipable where educationary science in 26% priorities in strend 12:302.12 P < 0.01). Is the grants expressinglish where educationary science its With partner was also grant strend 12:302.12 P (2010). The grant equipable where educationary science its 25% education internel 525:63; P < 60(). |
| | Conclusions: In this toody, HW policies and calcustors of HCW applicaturity improved DEW addressees to the HW protocol. Jour- ever, when performance feedback was incorporated, the HW compliance invessed to a genare depres. We identified that advantagences apport provides a possible tail lengence in efform to approve HW addressee. User J laters Control (2003):18:59(2). |
| | |

| 29.6% 3/89 to 1/05 68.9% 2.33 2,12 - 2,56 0.000 14 7.8% 2/04 to 10/04 54.5% 7.01 4,22 - 11,67 0.000 10/05 to 10/05 to 10/05 10 | Country | City | Hospital | Baseline period | Pre | Interventio n period | Post | RR | 95% CI | P Value |
|--|-----------|-----------------|---|--------------------|-------|-------------------------|-------|------|--------------|------------|
| 29.6% 3/99 to 1/05 68.9% 2.33 2,12 - 2,56 0.000 44 7.8% 2/04 to 10/04 54.5% 7.01 4,22 - 11,67 0.000 is 2.2% 10/05 to 9.6% 4.28 1,63 - 11,22 0.001 9.6% 11/5 to 6/6 28.3% 2.95 1,33 - 6,53 0.0050 | | | | | | | | | | |
| 14 7.8% 2/04 to 10/04 54.5% 7.01 4.22 - 11.67 0.000 i 2.2% 1005 to 12/05 9.6% 4.28 1.63 - 11.22 0.001 9.6% 11/5 to 6/6 28.3% 2.95 1.33 - 6.53 0.0050 | Argentina | Bernal | Bernal | 4/99 to 5/99 | 24.0% | 6/99 to 8/06 | 65.3% | 2.71 | 2,12 - 3,48 | 0.000 |
| 2 2% 1005 b 9.6% 4.28 1.63 - 11.22 0.001 9.6% 11/5 to 6/6 28.3% 2.95 1.33 - 6.53 0.0050 | Argentina | Buenos Aires | Colegiales Medical Center | 9/00 to 2/01 | 29.6% | 3/99 to 1/05 | 68.9% | 2.33 | 2,12 - 2,56 | 0.000 |
| i 2.2% 12:05 9.6% 4.28 1,63 - 11,22 0.001 9.6% 11/5 to 6/6 28.3% 2.95 1,33 - 6,53 0.0050 | Argentina | Buenos Aires | Estrada Medical Center | 10/03 to 1/04 | 7.8% | 2/04 to 10/04 | 54.5% | 7.01 | 4,22 - 11,67 | 0.000 |
| | Argentina | Avellaneda | Fiorito Hospital | 7/05 to 9/05 | 2.2% | | 9.6% | 4.28 | 1,63 -11,22 | 0.001 |
| 36.4% 10/4 to 7/5 48.0% 1.32 0.88 - 1.98 0.1800 | Argentina | Lanús | Narciso López Hospital | 7/5-10/5 | 9.6% | 11/5 to 6/6 | 28.3% | 2.95 | 1,33 - 6,53 | 0.0050 |
| 1. | Argentina | Avellaneda | Presidente Perón Hospital | 7/4-09/4 | 36.4% | 10/4 to 7/5 | 48.0% | 1.32 | 0.88 - 1.98 | 0.1800 |
| | Argentina | Lanús | Narciso López Hospital Presidente Perón | 7/5-10/5 | 9.6% | 11/5 to 6/6 | 28.3% | 2.95 | 1,33 - 6,53 | |

| Country | City | Hospital | Baseline period | Pre | Intervention period | Post | RR | 95% CI | P Valu |
|----------|-------------------|-------------------------------------|--------------------|-------|---------------------|-------|------|-------------|-----------|
| Brazil | Sao Paulo | Santa Marcelina Hospital (UTI 1) | 8/04 to 11/04 | 47.5% | 12/04 to 4/06 | 68.5% | 1.44 | 1,21 - 1,71 | 0.00 |
| Brazil | Porto Alegre | Porto Alegre General Hospital | 8/4-11/4 | 29.0% | 12/4 to 2/6 | 53.9% | 2.01 | 1.71 - 2.37 | 0.00 |
| Brazil | Rio de Janeiro | HUCFF | 4/3 | 56.7% | 5/3 to 6/3 | 71.5% | 1.26 | 0.98 -1.62 | 0.070 |
| Colombia | Bogotá | San Ignacio Hospital | 8/03 to 9/03 | 18.4% | 10/03 to 1/04 | 35.3% | 1.92 | 1.45 - 2.54 | 0.00 |
| Mexico | Mexico | General Hospital of Mexico | 6/02 to 7/02 | 24.0% | 08/02 to 11/03 | 80.8% | 3.37 | 2,46 - 4,63 | 0.00 |
| Mexico | Mexico | Celaya Hospital | 1/04 to 5/04 | 10.7% | 6/04 to 8/04 | 53.5% | 4.98 | 3,25 - 7,63 | 0.00 |
| Mexico | Mexico | Irapuato Hospital | 11/03 to 2/04 | 33.3% | 3/04 to 5/05 | 47.9% | 1.44 | 1,07 - 1,93 | 0.01 |
| Mexico | Mexico | De la Mujer Hospital (NEO) | 10/03 to 2/04 | 43.8% | 3/04 to 6/04 | 66.6% | 1.52 | 1,33 - 1,74 | 0.00 |

| Country | City | Hospital | Baseline period | Pre | Intervention period | Post | RR | 95% CI | P Valu |
|----------------|-----------------|--|--------------------|-------|---------------------|-------|------|-------------|-----------|
| Mexico | Mexico | De la Mujer Hospital (UCI) | 10/03 to 2/04 | 35.7% | 3/04 to 6/04 | 60.0% | 1.68 | 1,45 - 1,95 | 0.00 |
| Mexico | Mexico | IMSS- Especialidade s | 10/02 to 1/03 | 46.6% | 2/03 to 11/03 | 76.0% | 1.63 | 1,40 - 1,89 | 0.00 |
| Mexico | Mexico | IMSS- Mancera | 10/02 to 1/03 | 35.5% | 2/03 to 11/03 | 69.9% | 1.97 | 1,29 - 3,00 | 0.00 |
| Mexico | Mexico | La Raza Medical Center | 8/05 to 9/05 | 43.0% | 10/05 to 04/06 | 79.1% | 1.84 | 1,43 - 2,36 | 0.00 |
| Perú | Lima | INEN Hospital | 5/04 to 8/04 | 37.1% | 9/04 to 1/06 | 65.9% | 1.77 | 1.01 - 3.13 | 0.04 |
| Perú | Lima | San Pablo Clinic | 2/04 to 5/04 | 74.9% | 6/04 to 10/05 | 89.2% | 89.2 | 1,08 - 1,32 | 0.00 |
| Perú | Trujillo | Víctor Lazarte Hospital | 1/04 to 3/04 | 40.9% | 4/04 to 6/04 | 52.6% | 1.29 | 1.01 – 1.63 | 0.03 |
| El Salvador | San Salvador | Nat. Child.'s Ho. Benjamin Bloom | 1/7 | 38.5% | 2/7 to 3/7 | 49.3% | 1.28 | 0.92 - 1.78 | 0.13 |

| Country | City | Hospital | Baseline period | Pre | Intervention period | Post | RR | 95% CI | P Value |
|-------------|-----------|---------------------------------|--------------------|-------|---------------------|-------|------|-------------|------------|
| Philippines | Quezon | Saint Luke's (PED) | 12/05 to 1/06 | 32.7% | 2/06 to 10/06 | 70.6% | 2.16 | 1.32 - 3.53 | 0.0017 |
| India | Bangalore | Wockhardt Medical Center | 11/04 to 12/04 | 54.8% | 1/05 to 5/06 | 95.2% | 1.74 | 1,40 - 2,16 | 0.000 |
| India | Kolkata | AMRI Hospitals | 5/6 to 7/6 | 71.5% | 8/6 to 4/7 | 73.9% | 1.03 | 0.97 - 1.11 | 0.3337 |
| Pakistan | Karachi | Liaquat National Hospital | 1/6 to 4/6 | 25.8% | 5/6 to 10/6 | 42.0% | 1.63 | 1.33 - 1.99 | 0.0000 |
| Turkey | Samsun | Ondokuz Mayis | 1/4-9/4 | 70.4% | 10/4 to 9/6 | 82.5% | 1.17 | 1.05 - 1.31 | 0.0054 |
| Turkey | Sanliurfa | Harran University | 5/5-10/5 | 30.7% | 11/5 to 4/6 | 56.1% | 1.83 | 1,34 - 2,50 | 0.000 |

| Country | City | Hospital | Baseline period | Pre | Intervention period | Post | RR | 95% CI | P Valu |
|---------|----------|---|--------------------|-------|------------------------|-------|------|-----------------|-----------|
| Turkey | Trabzon | Karadeniz University | 9/04 to 11/04 | 36.9% | 12/04 to 6/05 | 47.0% | 1.27 | 1,00 - 1,62 | 0.046 |
| Turkey | Ankara | Hacettepe University School of Medicine | 5/04 to 7/04 | 28.5% | 8/04 to 10/04 | 40.8% | 1.43 | 1,17 - 1,75 | 0.000 |
| Turkey | Ankara | Ankara Univ.School of Medicine Ibni-Sina Hospital | 8/03 to 11/03 | 19.2% | 12/03 to 12/05 | 46.2% | 2.4 | 2,00 - 2,87 | 0.000 |
| Turkey | Antalya | Akdeniz University | 6/04 to 11/04 | 4.2% | 12/04 to 9/06 | 16.0% | 3.85 | 1.40 - 10.59 | 0.004 |
| Turkey | Istanbul | Haydarpasa Hospital | 10/03 to 3/04 | 6.9% | 4/04 to 9/06 | 43.1% | 6.23 | 4.86 - 7.98 | 0.000 |
| Turkey | Istanbul | Hospital | | | 4/04 to 9/06 | | | | 0.0 62 |

Surveillance Outcome Surveillance

•The second step is to implement targeted specific infection control practices that have been shown to prevent HAI.

•INICC have evaluated hospitals in which outcome and process surveillance have been the driving force to reduce infection risk and infection-related mortality.

Surveillance

Process Surveillance

In Argentina, a program was developed consisting of frequent focused education
 of healthcare workers, process surveillance and performance feedback.


 Simultaneously, HAI rates were measured at baseline and during the intervention to determine whether improved compliance would be associated with a reduction in HAI. A 42% relative reduction in HAI rates was reported from conducting process surveillance and emphasizing compliance with hand hygiene.

Surveillance

Process Surveillance

 It was the first study of reduction in HAI made by improving hand hygiene in Latin America and the investigators inferred that similar improvement could occur in similar developing countries.

The authors found lower adherence among physicians, which is similar to results reported in industrialized countries.



| | | Hospital | Baseline Rate | Intervention Rate | Reduction Rate | RR | CI (95%) | P Value | Re |
|-----------|-------------------|--|------------------------------|--|--------------------|---------------------------|---------------------------|------------------------------------|------------------|
| Argentina | Bs. As. | Colegiales Medical Center | 47.55 p/1000 bed- days | 27.9 p/1000 bed-days | 41% | 0.59 | 0.46 - 0.74 | <0.0001 | 1 |
| Brazil | Porto Alegre | Porto Alegre G. Hospital | 19.8% | 4.8% | 76% | 0.24 | 0.07 - 0.80 | 0.0113 | 2 |
| Colombia | Bogotá | La Victoria | 21.3% | 6.2% | 71% | 0.29 | 0.10 - 0.85 | 0.0161 | 3 |
| | | n S, Safdar N. Red Am J Infect Control | | infection with improv | ed hand hygiene in | intensive | care units c | f a tertiary care | |
| in a Ho | spital in Brazil. | Findings of the INK | C. In: Proceedings a | eness of Outcome a and Abstracts of the 3 e 24-28; San Jose, U | 4th Annual Scienti | | | | Rates |
| a Hosp | ital of Colombia | ME, Rosenthal VE E. Findings of the IN Is and Chemothera | ICC. In: Proceedings | tcome and Process and Abstracts of the | 47th Annual Scien | ducing De tific Meetin | vice-Associang of the Int | ated Infection F erscience Conf | tates i erenc |

| | Hospital | Baseline Rate | Intervention Rate | Reduction Rate | RR | CI (95%) | P Value | Ref |
|----------------------|---|--|--|--|--|---|--|---|
| Bangalore | Wockhardt Hospital | 2.5% | 0.17% | 99.3% | 0.07 | 0.01 - 0.30 | < 0.0001 | 1 |
| Kolkata | ARMI Hospital | 12 % | 5.3% | 55% | 0.45 | 0.22 - 0.90 | 0.0200 | 2 |
| Vellore | Christian Medical College | 16.1 p/1000 bed-days | 5.1 p/ 1000 bed-days | 68% | 0.32 | 0.09 - 1.06 | 0.0481 | 3 |
| México D.F. | De la Mujer Hospital | 12.96% | 4.95% | 62% | 0.38 | 0.15 - 0.99 | 0.0393 | 4 |
| ndian Critical Patie | nts. In: Proceeding | s and Abstract of 7 | | | | | | |
| osocomial Infection | Rates in a Hospita | al in India. Findings | s of the International M | losocomial Infection | n Control | Consortium | (INICC). In: P | roceedi |
| d Infection Rates in | a Hospital of India | . Findings of the I | NICC. In: Proceedings | and Abstracts of | the 47th A | nnual Scien | | |
| | Kolkata Vellore México D.F. thy M. Javeli V. F ndrar Official Pale spectratus, Step Fasta, Step Rosenhal V.O. e Consenhal V.O. e | Hospital Kolkata ARMI Hospital Vellore Christian Medical College México De la D.F. Mujer Hospital Mujer Hospital Recentral V, et al. Enclosedas Generative V, et al. Enclosedas Recentral V, et al. Enclosedas Recentral V, et al. Enclosedas Recentral V, et al. Enclosedas Recentral V, et al. Enclosedas act of her The Annual Scientific Net | Hospital Hospital Kolkata ARMI Hospital 12 % Vellore Christian Medical College 16.1 p/1000 bed-days México De la D.F. 12.96% Mujer Hospital Thy Jawai V, Resembla V, et al. Process and Datact of Gale Estar, Stelenboor, South Africa, 2006, p. 50. 12.96% Mujer Hospital The Resembla VD, et al. Effectivenes of Obscore and Pp catch of the The Annual Scientific Meeting of The Society of Infection Rates in a Hospital of India. Findings of the of Infection Rates in a Hospital of India. Findings of the Collement Of Antimicrobial Agents and Chemother | Longenter Hospital Longenter Kolkata ARMI Hospital 12 % 5.3% Vellore Christian Medical College 16.1 5.1 p/ 1000 bed-days México De la D.F. 12.96% 4.95% Might 12.96% 4.95% Mexico De la Interference 14.000m and Abata 206.9.50 4.95% Mexico De la Interference 12.96% 4.95% Might Assential V, et al. Process and Datacet of Th Annual Meeting of gate Eater, Steinetosch, Souh Africz, 206.9.50 50.0000 models for Heathcare Epide acts of the Th Annual Scientific Meeting of The Society for Heathcare Epide conference on Antimicrobia Agrees and Chemotherapy. Or Selentiethere of Infection Rates in a Heapital of India. Findings of the NICC. In: Proceedings | Mospital International and the second s | Mospital Diff Diff Diff Kolkata ARMI Hospital 12 % 5.3% 55% 0.45 Vellore Christian Medical 16.1 p/1000 bed-days 5.1 p/1000 bed-days 0.32 México D.F. De la Mujer Hospital 12.96% 4.95% 62% 0.38 México D.F. De la Mujer Hospital 12.96% 4.95% 62% 0.38 México D.F. Electrones dAtascator And Feedback E 16.1 molecular datascator And Feedback E 0.32 Mexico D.F. Electrones and Abatract of Th Annual Metring of the International Feedback E 0.38 0.32 Resentu V, Resentu V, Electrones and Abatract of Th Annual Metring of the International Feedback E 0.38 0.38 Resentu V, Electrones and Abatract of The Society for Healthcare Epidenburg of Anterics. 2007 A atac of the Th Annual Scientific Heeling of The Society for Healthcare Epidenburg of Anterics. 2007 A atac of the Th Annual Scientific Heeling of The Society for Healthcare E (Anterics And Abatracts of the 4Th Annual Scientific Heelinger Annual Abatract (Cr. In Proceeding and Abatracts of the 4Th Annual Abatracts of the 4Th Annual Abatracts of the 4Th Annual Abatract (Cr. In Proceeding and Abatracts of the 4Th Annual Abatract (Cr. In Proceeding and Abatracts of the 4Th Annual Abatract (Cr. In Proceeding and Abatracts of the 4Th Annual Abatract (Cr. In Proceeding and Abatra | Model Hospital Link Link Link Link 0.30 Kolkata ARMI Hospital 12 % 5.3% 55% 0.45 0.22 - 0.90 Veliore Christian Medical College 16.1 5.1 p/ 1000 68% 0.32 0.09 - 1.06 México De la D.F. 12.96% 4.95% 62% 0.38 -1.6 Mexico De la D.F. 12.96% 4.95% 62% 0.38 -1.7 Organization critical Taleria: In: Proceeding and Advatacior 718 Annual Meeting of In Heimanical Technical Meeting of Spare Eatac. Shleinbork, Souh Africa. 208, p. 64. | Magenter Hospital Entry Entry <thentry< th=""> Entry Entry</thentry<> |

| Country | City | Hospital | Baseline Rate | Intervention Rate | Reduction Rate | RR | CI (95%) | P Value | Re |
|-----------------|--------------------|---|----------------------------|--|-------------------|------|-------------------|---------|----|
| Turkey | Trabzon | Karadeniz Technical University School of Medicine | 30 p/ 1000 bed-days | 18.3 p/ 1000 bed- days | 39% | 0.61 | 0.38 - 0.98 | 0.0380 | 1 |
| Turkey | Ankara | Ankara University School of Medicine Ibni-Sina | 56.7% | 37.8% | 39% | 0.61 | 0.44 - 0.84 | 0.0023 | 2 |
| Turkey | Ankara | Ankara University School of Medicine Ibni-Sina | 42.0 p/1000 bed-days | 25.5 p/1000 bed-days | 33% | 0.67 | 0.48 - 0.92 | 0.0133 | 2 |
| Turkey | Duzce | Duzce Medical School | 55.0% | 18.8% | 66% | 0.34 | 0.14 - 0.84 | 0.0142 | 3 |
| Turkey. In: Pro | ceedings and Al | | Annual Scientific | f Education and Pert Meeting of the Soci 90. | | | | | |
| Rates in a Tur | kish Hospital. Fir | | . In: Proceedings | ness of Outcome and and Abstracts of the | | | | | |




۲

The effect of process control on the incidence of central venous catheter-associated bloodstream infections and mortality in intensive care units in Mexico*


Francisco Higuera, MD; Victor Daniel Rosenthal, MD, MSc, CIC; Pablo Duarte, MD; Javier Ruiz, MD; Guillermo Franco, MD; Nasta Sardar, MD

who had a central version calleber (2VC) in place for at lenst 24. BSS per 1000 (Trd-sty, respectively; RE = 4.82; BSV). More that the set of the set of

Purpose: To assertian the effect of an infection control pro-minute process control on infestive care unit (00) rates $-1.08 + 2.08 \times p = .0000$, documentation of the duration of the historecontar devices (00%)-associated boltoware infection infestive transmission of the duration of the duration of the historecontar devices (00%)-associated boltoware infection infestive transmission of the duration of the historecontar devices (00%)-associated boltoware infection in Mexics: core nections surgestar U2 and one neurosurgical in Mexics: core nections surgestar U2 and nene neurosurgical in Mexics: core nections surgestar U2 and and the duration of the duration in Mexics: core nections surgestar U2 and nene neurosurgical in Mexics: core nections surgestar U2 and in the history surgest historic history surgestar and the duration of the intra a future intermetiation of process history core necessarily and the surgestar U2 and the surgest history in the history surgest and the history surgest history in the history surgest and the history surgest history in the history surgest and the history surgest history in the history surgest and the history surgest history in the history surgest and the history surgest history in the history surgest and the history surgest history in the history surgest and the history surgest history in the history surgest and the hist 32.8% -0.31;



Castañede Salogal A, Rosenthal VD, Camacho-Cosavalente L, Rodriguez T, Paredes-Goicochea I: Effectiveness Outcome Surveillance for Reducing Mortality in a Hospital of Peru. Findings of the INICC. In: Proceedings and Abstracts of the Arth Annual Scientific Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy: 2007 September 17-20; Chicago, U.S.A; 2007. 3. ness of




Surveillance

Process Surveillance


• Process surveillance for vascular and urinary catheter care, and mechanical ventilator care was also effective to reduce associated HAIs in several previous studies conducted in developing countries, such as Argentina, Brazil, Colombia, India, México, Turkey, among others.


Surveillance Process Surveillance

•Position of the urinary catheter regarding the leg, and position of urine bag regarding the bed and other practices were assessed and entered into a standard form by local researchers who observed healthcare worker (HCW) behaviors in the study units daily five days a week.










Surveillance Process Surveillance


•Position of the bed head, cleanliness of tubes, aspiration technique, hand hygiene with alcohol hand rub or hand washing with water and antiseptic soap prior to patient contact and other practices were assessed and entered into a standard form by local researchers who observed healthcare worker (HCW) behaviors in the study units daily five days a week.





| Country | City | Hospital | Baseline Rate | Intervention Rate | Reduction Rate | RR | CI (95%) | P Value | Ref |
|---|--|---|--|---|---|--|--|--|---|
| Argentina | Buenos Aires, Bernal | Bernal and Colegiales M. Centers | 51.28 p/1000 MV-days | 35.5 p/1000 MV-days | 31% | 0.69 | 0.49 - 0.98 | <0.003 | 1 |
| Colombia | Bogota | San Ignacio Hospital | 11.7 p/1000 MV-days | 4.2 p/1000 MV-days | 64% | 0.36 | 0.18 - 0.70 | 0.0016 | 2 |
| India | Vellore | Christian Medical College | 22.7 p/1000 MV-days | 6.6 p/1000 MV-days | 71% | 0.29 | 0.08 - 0.99 | 0.0358 | 3 |
| India | New Delhi | Escorts Heart Institute | 26.3 p/1000 MV-days | 10.9 p/1000 MV-days | 59% | 0.41 | 0.25 - 0.70 | 0.0005 | 4 |
| Turkey | Trabzon | Karadeniz Technical University | 19.6 p/1000 MV-days | 8.0 p/1000 MV-days | 59% | 0.41 | 0.21 - 0.80 | 0.0065 | 5 |
| Alvarez-Morens Proceedings an Sen N, Rosent Findings of the Chicago, U.S.A Mehta Y, Rose Proceedings an Koksal L Avdin | c, Rosenthal VD, et al Abstracts of the 17 hal VD, et al. Effecti INICC. In: Proceedia ; 2007. nthal VD, et al. Effect Abstract of 8th An K. Rosenthal VD, et al. | t al. Effectiveness of Out th Annual Scientific Meet reness of Outcome and F gs and Abstracts of the 4 siveness of Outcome and sual Meeting of the Interr al. Effectiveness of Outo | come and Process Su ing of The Society for Process Surveillance f 17th Annual Scientific Process Surveillance ational Federation Mi process Surveillance | sociated pneumonia in intr ssociated pneumonia in intr weillance for Reducing Ver Healthcare Epidemiology o re Reducing Ventilator-Ass Meeting of the Interscience for Reducing Ventilator-As seting of Infection Conrol; s veillance for Reducing Ven for Professionals in Infect | ntilator-Associated Pne of America; 2007 April 1 ociated Pneumonia and conference on Antimi sociated Pneumonia at 2007 Oct 18-21; Budap tilator-Associated Pneu | umonia in a 4-17; Baltim I Device-Ass crobial Agen nd Mortality i est, Hungar monia in a H | Colombian Ho ore, U.S.A.; 21 ociated Infecti Is and Chemor n a Hospital in r; 2007. Iospital of Turk | spital. Findings of 107. on Rates in a Hos herapy; 2007 Sep India. Findings of ev. Findings of th | the INICC pital of Inc tember 17 the INICC a INICC. I |




•Placement of gauze on IVD insertion sites, marking the date on the IV administration set, condition of the gauze dressing (the presence or absence of moisture, blood, gross soilage and the appearance of the insertion site is checked) and other practices were assessed and entered into a standard form by local researchers who observed healthcare worker (HCW) behaviors in the study units daily five days a week.









| Country | City | Hospital | Baseline Rate | Intervention Rate | Reduction Rate | RR | CI (95%) | P Value | Ref |
|--|---|---|--|--------------------------------|---------------------|--------------|----------------|-------------------|----------|
| Argentina | Bernal | Bernal Medical Center | 45.94 p/1000 CVC-days | 11.1 p/1000 CVC-days | 75% | 0.25 | 0.17 – 0.36 | <0.001 | 1 |
| Brazil | Sao Paulo | Santa Marcelina | 14 p/1000 CVC-days | 7.1 p/1000 CVC-days | 50% | 0.5 | 0.32 - 0.8 | 0.0029 | 2 |
| Colombia | Sucre | Santa María Medical Center | 54.8 p/1000 CVC-days | 6 p/1000 CVC-days | 89% | 0.11 | 0.01 - 0.98 | 0.0163 | 3 |
| India | Mumbai | Hinduja National Hospital | 12 p/1000 catheter days | 5.2 p/1000 catheter days | 57% | 0.43 | 0.22 - 0.83 | 0.0099 | 4 |
| Mexico | Mexico DF | Mexico's General Hospital | 46.3 p/1000 CVC-days | 19.5 p/1000 CVC-days | 58% | 0.42 | 0.27 – 0.66 | 0.0001 | 5 |
| in intensive can 2. Salomao R, 1 bloodstream int | e units in Argentin S Blecher, Da-Silv | infection control program a. Am J Infect Control 2 ra M, Villins M, Da-Silva tensive care units in on frection Control and Ep | 2003;31(7):405-9. EH, Rosenthal VI e bosoital in San P |). Education and perfor | mance feedback effo | ect on rates | of central vas | scular catheter- | associal |
| 3. Villamil Góm | ez W, Ruíz Verga | ra G, Marrugo Pertuz A 1s In New Born Intensiv | , Rosenthal VD. Er | ucation And Performa | nce Feedback Effect | On Rates | Of Central Va | | |
| Hospital of India | a. Findings of the | Effectiveness of Outcor INICC. In: Proceedings San Jose, U.S.A.: 2007 | and Abstracts of th | | | | | s in Infection Co | |

| Cou | ntry | City | Hospital | Baseline Rate | Intervention Rate | Reduction Rate | RR | CI (95%) | P Value | Ref |
|------|--------------------------|------------------------------------|---|--|--|---|---------------------------|----------------|---------------------------------------|-----------------------|
| Mex | ico | México D.F. | De la Mujer Hospital | 40.7 p/1000 CVC-days | 10.3 p/1000 CVC-days | 75% | 0.25 | 0.08 - 0.84 | 0.0152 | 1 |
| More | 0000 | Rabat | Ibn Sina- Medical ICU | 22.9 p/1000 CVC-days | 8.3 p/1000 CVC-days | 64% | 0.36 | 0.14 - 0.96 | 0.0334 | 2 |
| Turk | ey | Istanbul | Haydarpasa Hospital | 10 p/1000 CVC-days | 1.8 p/1000 CVC-days | 82% | 0.18 | 0.05 - 0.6 | 0.0016 | 3 |
| Turk | ey | Samsun | Ondokuz Mayis University Medical School | 29.1p/1000 CVC-days | 13.0 p/1000 CVC-days | 55% | 0.45 | 0.24 - 0.82 | 0.0076 | 4 |
| Re | duction in a althcare Ep | New Born Inter idemiology of Ar | sive Care Unit of One merica; 2005 April 9-1 | e Mexican Public Hos 2, 2005; Los Angeles | on Global Rates and Co pital. In: Proceedings a , California, United Sta | nd Abstracts of the 1 tes of America; 2005 | 5th Annua p. 123. | Scientific Me | eeting of the Soc | iety for |
| Ho | pital in Mo | | | | s Surveillance for Redu of 8th Annual Meeting | | | | | |
| Inte | nsive Care | Units of One Tu | urkish Hospital. In: Pr | oceedings and Abstra | k Effect on Rates of Ce icts of the 33rd Annual s of America; 2006. p. 2 | Scientific Meeting of | ter - Assor the Associ | ation for Prot | tream Infections essionals in Infe | in Adult ction Con |
| Inte | nsive Care | | | | Surveillance Plus Educ ing of the International | | | | | |

Conclusions

- In developing Countries HAI Rates and Bacterial Resistance are 3-5 times higher than international standards.
- The HAI increase length of stay (10 days), cost (\$US 5,000-12,000) and mortality (2 times)
- By applying Process Surveillance, plus Education and Performance Feedback we were able to increase HH compliance, and other Infection Control Interventions compliance.
- By applying Outcome and Process Surveillance plus Feedback we were able to reduce Mortality, Overall HAI rates, and Device Associated HAI rates.

- Every hospital are invited to incorporate into the INICC nonprofit research project.
- To incorporate, please only send an email to INICC with the following details:
 - -Your name,
 - -Your email,
 - -Your working phone number,
 - Your hospital's name,
 - -Your city.

www.INICC.org victor_rosenthal@inicc.org

90

Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com

89

Г

Thank you very much for your attention

www.INICC.org

victor_rosenthal@inicc.org victor_rosenthal@fibertel.com.ar

91

| August 16 | What Can We Learn From the History of Communicable Disease Control? (free teleclass) with Prof. Peter Curson, University of Sydney Broadcast live from the New Zealand Infection Control Association conference Sponsored by Johnson & Johnson |
|--------------|--|
| August 22 | ESBL's - Where are We Now? (free teleclass) with Dr. Fong Chiew, Christchurch, NZ |
| September 20 | Extreme Makeover - ICP Edition: Exploring Challenges to Our Identity in Infection Control (free teleclass) with Gwyneth Meyers, Calgary, Canada |
| September 24 | Infection Prevention: Challenging Behavior, Changing the Culture (free teleclass) with Dr. Elaine Larson, Columbia University |